Prescription drug · BLA
Yesafili (Aflibercept-jbvf) NDC 83257-013
Aflibercept 2 mg/.05mL · Injection, Solution · Intravitreal · Biocon Biologics Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 83257-013-01 | 8325700130183257001301 | 1 VIAL, SINGLE-DOSE in 1 CARTON (83257-013-01) / .05 mL in 1 VIAL, SINGLE-DOSEMarketed from Nov 3, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Yesafili
- Generic name (nonproprietary)
- aflibercept-jbvf
- Active ingredients
- Aflibercept — 2 mg/.05mL
- Dosage form
- Injection, Solution
- Route
- Intravitreal
- Labeler
- Biocon Biologics Inc.NDC labeler code 83257
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761274
- Marketing start
- Listing expires
- Other FDA classes
- Vascular Endothelial Growth Factor Inhibitors (Mechanism)
- Identifiers
- Product ID 83257-013_a1870a7c-4e43-7841-0770-f4f8d9a5d0bfSPL ID a1870a7c-4e43-7841-0770-f4f8d9a5d0bfSPL set ID 7d69a7b0-9511-c030-3b85-13b23f9d2980RxCUI 2749097, 2749104UNII 15C2VL427D
- Pharmacologic class
- Vascular Endothelial Growth Factor Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeMed-Code curated
J0178 — Injection, aflibercept, 1 mg
Billing unit: 1 mg. Units on the claim = dose given ÷ 1 mg.
EYLEA HD and aflibercept biosimilars have their own HCPCS codes.
- Administration
Intravitreal injection procedure (CPT 67028)
The intravitreal injection is reported as a separate procedure from the drug supplied.
- NDC on a medical claim
N483257001301followed by a unit qualifier and the quantityPackage 83257-0013-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
YESAFILI is indicated for the treatment of: YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: • Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) • Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) • Diabetic Macular Edema (DME) ( 1.3 ) • Diabetic Retinopathy (DR) ( 1.4 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR)
Excerpt only. Read the full label for complete information.
About NDC 83257-013
- What is NDC 83257-013?
- 83257-013 is the product NDC for Yesafili (aflibercept-jbvf), Aflibercept 2 mg/.05mL injection, solution, listed with the FDA by Biocon Biologics Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Yesafili (Aflibercept-jbvf).
- What is the active ingredient?
- Aflibercept.
- Who is the labeler?
- Biocon Biologics Inc., NDC labeler code 83257. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Yesafili?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Yes: J0178, Injection, aflibercept, 1 mg. See Billing references above.
Related NDCs: other Yesafili products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Yesafiliaflibercept-jbvf | Aflibercept 2 mg/.05mL | Injection, SolutionIntravitreal | Biocon Biologics Inc. | 83257-035 | 83257-0035-41 |
Other NDCs under BLA 761274
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Yesafiliaflibercept-jbvf | Aflibercept 2 mg/.05mL | Injection, SolutionIntravitreal | Biocon Biologics Inc. | 83257-035 |